2019: Reasons to Attend CHI’s 11th annual Immunogenicity & Bioassay Summit

  • GAIN exclusive access to the FDA and have all your pressing questions answered.
  • ASSESS the clinical relevance of assays with in-depth case studies from Eli Lily and MedImmune.
  • HEAR from key leaders in the fields of bioassay design, statistics, cell therapies (encompassing immunotherapies), gene therapies and antibodies.
  • APPLY bispecific technology to modulate the immune response for therapeutic intervention.
  • LEARN new approaches for developing NAbs: Genentech, Merck, Regeneron and SVAR all share their strategies.
  • DISCOVER how to overcome challenges in validating bioassays.
  • LEARN safety considerations for biotherapeutics from Rakesh Dixit, PhD, Vice President and Head of Biologics Safety Assessment at MedImmune.
  • HEAR how Pfizer, Bristol-Myers Squibb and Selecta Biosciences translate their data into the clinic.
  • DISCOVER how quality by design (QbD) and statistics can be applied to assay development and reference bridging.
  • LEARN how to integrate prediction technologies into the drug development process. 
  • UNDERSTAND the immunology of immunotherapeutics for cancer: potential for success and dangers of getting it wrong.
  • ACCELERATE the speed of bioassay optimization and validation through new developments.
  • ASSESS biopharmaceutical product immunogenicity: what causes it and what are the safety and efficacy consequences?
  • LEARN how to navigate the new regulatory guidance.
  • EXPLORE the role of the innate immune system and implications for biotherapeutics.
  • IMPROVE your bioassay results through applying new standards from NIBSC and USP.
  • PARTICIPATE in several panel & roundtable breakout discussions on a variety of topics
  • VIEW several exhibits and posters
  • NETWORK with 250+ global attendees
  • and a lot more!